EA201291050A1 - Комбинация лекарств с протеинсвязывающими пролекарствами - Google Patents

Комбинация лекарств с протеинсвязывающими пролекарствами

Info

Publication number
EA201291050A1
EA201291050A1 EA201291050A EA201291050A EA201291050A1 EA 201291050 A1 EA201291050 A1 EA 201291050A1 EA 201291050 A EA201291050 A EA 201291050A EA 201291050 A EA201291050 A EA 201291050A EA 201291050 A1 EA201291050 A1 EA 201291050A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
protectives
medicinal
protein
composition
Prior art date
Application number
EA201291050A
Other languages
English (en)
Other versions
EA026870B1 (ru
Inventor
Феликс Крац
Original Assignee
Ктб Туморфоршунгсгезелльшафт Мбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ктб Туморфоршунгсгезелльшафт Мбх filed Critical Ктб Туморфоршунгсгезелльшафт Мбх
Publication of EA201291050A1 publication Critical patent/EA201291050A1/ru
Publication of EA026870B1 publication Critical patent/EA026870B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к композиции и комбинации, включающей по меньшей мере одно первое лекарственное средство и по меньшей мере одно протеинсвязывающее пролекарство, где протеинсвязывающее пролекарство содержит протеинсвязывающую группу, второе лекарственное средство и линкер, который в организме может быть расщеплен ферментативным путем, гидролитически или рН-зависимым образом; а также к набору и фармацевтической композиции, включающей упомянутую композицию или комбинацию.
EA201291050A 2010-04-19 2011-04-13 Комбинация и фармацевтическая композиция для лечения опухолей EA026870B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004143A EP2382993A1 (en) 2010-04-19 2010-04-19 Combination of drugs with protein-binding prodrugs
PCT/EP2011/001874 WO2011131314A1 (en) 2010-04-19 2011-04-13 Combination of drugs with protein-binding prodrugs

Publications (2)

Publication Number Publication Date
EA201291050A1 true EA201291050A1 (ru) 2013-05-30
EA026870B1 EA026870B1 (ru) 2017-05-31

Family

ID=42782052

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291050A EA026870B1 (ru) 2010-04-19 2011-04-13 Комбинация и фармацевтическая композиция для лечения опухолей

Country Status (10)

Country Link
US (2) US10220101B2 (ru)
EP (2) EP2382993A1 (ru)
JP (1) JP5808391B2 (ru)
KR (1) KR101831465B1 (ru)
CN (1) CN102939109B (ru)
AU (1) AU2011244764B2 (ru)
BR (1) BR112012026724A2 (ru)
CA (1) CA2796969C (ru)
EA (1) EA026870B1 (ru)
WO (1) WO2011131314A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP2382993A1 (en) * 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
EP2630971B8 (en) * 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems
CA2912908C (en) 2013-06-05 2021-06-08 Cytrx Corporation Cytotoxic agents comprising covalently protein binding groups for treating brain cancer
WO2015009902A1 (en) * 2013-07-19 2015-01-22 The Johns Hopkins University Compositions comprising exemestane and novel methods of use
CN107614002B (zh) * 2015-05-29 2022-01-04 箭头药业股份有限公司 生物学可切割四肽连接剂
CN108218932B (zh) * 2017-12-27 2019-01-04 北京大学 凝集素受体介导的癌症预靶向治疗药物
CN108059651B (zh) * 2018-01-04 2021-04-20 东莞东阳光保健品研发有限公司 分离的呈味肽及其制备方法和应用
CN108187063B (zh) * 2018-01-09 2020-09-08 沈阳药科大学 白蛋白结合型抗肿瘤药-马来酰亚胺分子前药
CN114437153B (zh) * 2022-01-25 2023-10-27 沈阳药科大学 一种阿霉素-单胺氧化酶抑制剂前药化合物及其制备方法和应用
CN115212314B (zh) * 2022-06-14 2024-04-30 沈阳药科大学 一种白蛋白结合型抗肿瘤药及其纳米复合物、制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248507A (en) 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
US20040219173A1 (en) 2000-11-22 2004-11-04 Bass Ralph L. Method for treating hiv
JP2003043023A (ja) 2001-08-03 2003-02-13 Arigen Inc 血液中のオルセニルアルデヒド化合物の定量法
GB0217347D0 (en) 2002-07-26 2002-09-04 Univ Edinburgh Novel albumins
PT1592439E (pt) 2003-02-13 2007-06-22 Octapharma Ag Processo para a preparação de uma solução de albumina
US20050250835A1 (en) * 2004-04-23 2005-11-10 Yuqiang Wang Novel tumor-selective chemotherapeutic agents
PL3248600T3 (pl) * 2005-02-18 2020-09-07 Abraxis Bioscience, Llc Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona
WO2007005941A2 (en) * 2005-07-05 2007-01-11 President And Fellows Of Harvard College Liver targeted conjugates
US20070190068A1 (en) * 2005-10-10 2007-08-16 Richard Hart uPAR-binding molecule-drug conjugates and uses thereof
EP3453405A1 (en) * 2007-02-16 2019-03-13 Vergell Medical S.A. Dual acting prodrugs
EP2604284A1 (en) * 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
JP2010527357A (ja) 2007-05-17 2010-08-12 セラヴァンス， インコーポレーテッド 腸の前処置のための運動促進剤
WO2009097397A2 (en) * 2008-01-30 2009-08-06 Dyax Corp. Metalloproteinase binding proteins
US20110117009A1 (en) * 2008-03-31 2011-05-19 Freie Universität Berlin Drug conjugates with polyglycerols
EP2382993A1 (en) * 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
EP2630971B8 (en) * 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems

Also Published As

Publication number Publication date
US20130040905A1 (en) 2013-02-14
KR101831465B1 (ko) 2018-02-22
BR112012026724A2 (pt) 2018-05-15
EP2560688B1 (en) 2017-11-01
WO2011131314A1 (en) 2011-10-27
KR20130106761A (ko) 2013-09-30
US10220101B2 (en) 2019-03-05
AU2011244764B2 (en) 2016-10-06
EA026870B1 (ru) 2017-05-31
CA2796969C (en) 2019-03-05
CN102939109B (zh) 2015-12-02
EP2560688A1 (en) 2013-02-27
JP5808391B2 (ja) 2015-11-10
EP2382993A1 (en) 2011-11-02
CN102939109A (zh) 2013-02-20
US10426841B2 (en) 2019-10-01
JP2013527838A (ja) 2013-07-04
AU2011244764A1 (en) 2012-11-01
CA2796969A1 (en) 2011-10-27
US20170319707A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
EA201291050A1 (ru) Комбинация лекарств с протеинсвязывающими пролекарствами
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201291168A1 (ru) Фармацевтические композиции и способы их получения
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201170441A1 (ru) Терапевтические противовирусные пептиды
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
BR112015018504A2 (pt) moduladores de flap
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU